Published in Vaccine Weekly, October 18th, 2006
According to the report from Germany, "Biological effects of substance P (SP) are mediated by the neurokinin-1 (NK1) receptor that exists as a full-length and as a carboxy-terminally truncated isoform in humans. Although NK1 receptor mRNA and binding sites have been detected in certain malignancies, little is known about the cellular and subcellular localization of NK1 receptor protein in human neoplastic tissues."
"We developed and characterized a novel anti-peptide antibody to the carboxy-terminal region of the human full-length NK1 receptor,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly